Pacer Advisors, Inc. Cytom X Therapeutics, Inc. Transaction History

Pacer Advisors, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 21, 2021	SELL	$6.33 - $9.91 $24,091 - $37,717	-3,806 Closed	0 $0
Q1 2021 Apr 05, 2021	BUY	$6.6 - $9.0 $6,600 - $9,000	1,000 Added 35.64%	3,806 $29,000
Q4 2020 Jan 20, 2021	BUY	$6.47 - $7.9 $2,368 - $2,891	366 Added 15.0%	2,806 $18,000
Q3 2020 Oct 19, 2020	BUY	$6.55 - $8.83 $15,982 - $21,545	2,440 New	2,440 $16,000
Q4 2018 Feb 13, 2019	SELL	$12.69 - $18.61 $56,229 - $82,460	-4,431 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$18.04 - $26.41 $79,935 - $117,022	4,431 New	4,431 $82,000
Q1 2018 May 14, 2018	SELL	$21.76 - $34.22 $11,424 - $17,965	-525 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$19.0 - $23.09 $9,975 - $12,122	525	525 $11,000

49.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $55.4M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Pacer Advisors, Inc. with notifications on news.